Innovating Cancer Care, By Design

Mural Oncology immunotherapy employee sitting at desk smiling and folded hands

Our Mission

Unlocking the value of immunotherapy for more patients

At Mural Oncology we are leveraging our industry-leading protein engineering platform to reimagine cytokine-based immunotherapies for the treatment of cancer. Our mission is simple: to create novel immunotherapies that can change patients’ lives so they can get back to what matters most: living.

white paint stroke bottom

We are

Devoted to advancing the field of cancer science

We leverage our expertise in cytokine biology, immune cell modulation and our unmatched protein engineering capabilities to develop first- and best-in-class immunotherapies. Our goal is to deliver meaningful, clinical benefit across a wide range of cancers, including tumor types where immunotherapies have previously not been effective.

Woman using lab equipment in a lab setting studying cancer immunotherapy options
Digital scan of a cancerous tumor before immunotherapy
microscopic scan of a cancerous tumor before immunotherapy
White paint stroke top

Explore

Our Pipeline

We are developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available today.

Candidates Discovery Preclinical Phase 1 Phase 2 Phase 3
  • Nemvaleukin alfa Platinum-Resistant Ovarian Cancer*
  • Nemvaleukin alfa Mucosal Melanoma
  • IL-18
  • IL-12
Mural Oncology's Treatment Candidate Pipeline

*In combination with pembrolizumab
Last updated: January 2024

white paint stroke bottom

Featured

Mural Oncology News

Learn about our latest milestones and achievements.

Woman using lab equipment in a lab setting studying cancer immunotherapy options
calendar icon

January 8, 2024

Mural Oncology Announces Enhancements to Late-Stage Clinical Trials

>> Read the Press Release
Mural Oncology logo over water color themed background
calendar icon

November 15, 2023

Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies

>> Read the Press Release
Mural Oncology logo over water color themed background
calendar icon

October 31, 2023

Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement

>> Read the Press Release

Are you inspired to make a difference for people living with cancer?

Bring your passion and talent to help us achieve our mission. Visit our Careers page to learn more about what it's like to be part of Mural Oncology and explore current opportunities to join our team.

Portrait of Rita a Mural Oncology employee who studies cancer immunotherapy

Discover

Our Clinical Trials

Clinical trials are currently underway to explore the safety and efficacy of nemvaleukin alfa, a novel, engineered IL-2 variant immunotherapy, in difficult-to-treat cancers with high unmet need.

Dropper seen adding liquid to vial.
Artistry logo

-7

ARTISTRY-7 is enrolling adult patients with advanced or metastatic (cancer that has spread) epithelial ovarian, fallopian tube, or primary peritoneal cancer that has become resistant to platinum-based therapy.

Lab science research glass items adding drop to one of several test tubes.
Artistry logo

-6

ARTISTRY-6 is enrolling adult patients with advanced or inoperable cutaneous and mucosal metastatic melanoma who have previously received anti-PD-[L]-1 therapy.

Needle syringe in a vial.
Artistry logo

-3

ARTISTRY-3 is a phase 2 study evaluating clinical and immunologic activity with less frequent IV dosing in people with advanced solid tumors.

I am motivated and inspired by knowing that what I'm doing in the laboratory will have a positive impact for communities and patients that are struggling with cancer. Knowing that I can make a difference is really powerful and rewarding.

Pinar Gurel, Research